
Mercedes Says Its Hi-Po EVs Need to Be an 'AMG First, EV Second'
Schiebe said AMG wants the EVs to deliver the same level of feedback as its gas-powered cars, pointing to sound and repeatable performance as key factors.
He also reiterated that the V-8 engine will live on at AMG and will not necessarily need to be hybridized.
While Mercedes already attached the AMG name to potent versions of its existing electric cars, such as the Mercedes-AMG EQS53 sedan, the German performance brand will begin a more seismic shift when the dedicated AMG.EA electric architecture arrives next year. The AMG.EA platform will underpin two high-performance EVs, with a low-slung sedan due in 2026, shortly followed by an SUV. We spoke with AMG boss Michael Schiebe at the Miami Grand Prix to learn how the performance brand will ensure its EVs maintain the same exhilarating experience as its gas-powered cars.
AMG Goes Electric
"We said when we come to the market with our first high-performance electric car, it needs to be a real high-performance car," Schiebe explained. "I always say it needs to be an AMG first and an EV second."
Mercedes-Benz
The first car on the AMG.EA platform will be a high-performance sedan arriving in 2026.
There isn't much known just yet about the AMG.EA platform, other than its use of high-voltage batteries for rapid recharging and lightweight, albeit power-dense, axial-flux motors. But Schiebe claims the platform will create EVs that are "not comparable to all the electric cars that you have in the market right now" and that will be "playing with all of your senses."
Schiebe declined to specify exactly how AMG will make the electric sedan engaging to drive, but he gave a few clues. "It's the sound, it's the feedback that you get from the car," he noted. "One thing that is of high importance to us is continuous performance. Most electric cars on the market, they are capable of accelerating very fast. You can do that once, maybe you can do it twice, but if you try to repeat that, most of them quickly lose steam."
The AMG.EA platform will focus on delivering repeatable performance, and the German brand has its eye on the ultimate measuring stick—the iconic Nürburgring race track. "If you drive a high-performance [gas-powered] AMG car, you can take the car on the Nordschleife, and you're accelerating, braking, accelerating, braking, accelerating, braking," Schiebe said. "This is what the AMG.EA needs to deliver."
Mercedes-AMG
The electric AMG sedan will take inspiration from the 2022 Vision AMG concept.
We also asked Schiebe if AMG is considering fake shifts for its electric performance cars in a similar manner to the Hyundai Ioniq 5 N's "N e-Shift" mode. Schiebe wouldn't confirm anything, but he said the brand wouldn't write off the idea and emphasized that its EVs will retain the same degree of feedback as its gas-powered cars.
He concluded with a promising statement. "We just recently had some U.S. dealers actually given the chance to drive some of those cars, and when they got out of the car, all of them were smiling," Schiebe said. "They said that this is completely changing what they thought about electric cars."
The V-8 Is Not Dead Yet
Despite plans for AMG-specific EVs, Schiebe also reiterated that the V-8 engine will live on. "We have just launched the GT [coupe] last year," he said. "So there is some years to come with the V-8." While Schiebe noted Europe's plan to ban combustion engines in new cars in 2035, he pointed out that the United States doesn't have the same mandate and said there isn't a specific end date for eight-cylinder engines.
We previously theorized that the AMG.EA-based sedan would spell the end for the AMG GT 4-Door model, but Mercedes' commitment to the V-8 means that isn't necessarily the case. "Let's see how long we continue with a GT 4-Door," he said. "Maybe there is a successor, but I don't want to speculate about that." Regardless, it seems the current GT 4-Door will continue alongside the EV sedan for the foreseeable future.
Mercedes-AMG
The gas-powered AMG GT 4-Door could live for longer than previously thought.
AMG will obviously need to update its V-8 in the coming years to comply with tighter regulations, particularly in Europe. But Schiebe also sees room for even more performance from its eight-cylinder engines, which could see them employed in new places in the AMG family. "We are in the midst of developing our next generation of the V-8," he said. "And I see a lot of positions within our existing portfolio, or maybe even new ones, where we could actually imagine to have a V-8." Could this mean a return for the V-8 in the C63 sports sedan? Schiebe wouldn't confirm, but we have our fingers crossed.
When Mercedes confirmed a next-generation V-8 engine earlier this year, it was described as a "high-tech electrified" powertrain. "I see there is a lot of technological advancement coming in the future," Schiebe said. Interestingly, however, he also said "I don't say that we necessarily need to go that far on hybridization," noting that drivers who like to take their cars on track prefer something like the pure-gas GT63 Pro instead of the torqueier-but-heavier GT63 S E Performance hybrid.
Regardless of whether it will feature electric assistance or not, the continued existence of V-8s at Mercedes comes down to one key factor: the customers. "We see there is still the demand," Schiebe explained. "And my target is to fill customers' dreams."
Caleb Miller
Associate News Editor
Caleb Miller began blogging about cars at 13 years old, and he realized his dream of writing for a car magazine after graduating from Carnegie Mellon University and joining the Car and Driver team. He loves quirky and obscure autos, aiming to one day own something bizarre like a Nissan S-Cargo, and is an avid motorsports fan.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 minutes ago
- Yahoo
Pharma CEOs downplay impact of tariffs amid rising cost concerns
Despite analyst warnings of heightened financial risk, pharma CEOs across the US and Europe remain confident that the latest US-EU trade deal and associated tariffs will have limited impact. As per a new deal between the two global economic powerhouses, the EU will pay the US a tariff rate of 15% for pharmaceuticals. Medicines are the largest European exports to the US by value, and the EU accounts for approximately 60% of all pharmaceutical imports to the US. Top-selling drugs such as AbbVie's Humira (adalimumab), MSD's Keytruda (pembrolizumab), and Novo Nordisk's Ozempic (semaglutide), for example, are manufactured in Europe and sent to the US, representing billion-dollar markets. Analysts from GlobalData's Pharma Strategic Intelligence team say that: 'Companies manufacturing pharmaceutical products in Europe will need to anticipate financial exposure when planning launches in the US due to the unfavourable gross to net dynamics, weakened pricing leverage with US payers, and slower commercial uptake as insurers reassess cost effectiveness due to the tariffs.' US President Donald Trump has had a sharp focus on the pharma industry since assuming office. Analysts predict that adding duties to incoming goods will likely elevate costs across the pharmaceutical value chain, ultimately raising drug prices for patients. The policies make for interesting analysis when combined with his desire to cut prescription prices in the country. Diederik Stadig, sector economist for TMT & healthcare at ING, wrote in a July note: 'A tariff would hurt consumers most of all, as they would feel the inflationary effect of tariffs directly when paying for prescriptions.' The European Federation of Pharmaceutical Industries and Associations (EFPIA), for example, has maintained that tariffs on medicines are ineffective. The group says such policies only hinder patient access to medicines. GlobalData also forecasts disruptions to launch planning, particularly late-stage assets with EU-based manufacturing and production planned for entry into the US. R&D budgets of pharmaceutical companies are already under pressure and the firefighting of tariffs could place additional strain on resources. CEOs signal resilience CEOs of big pharma companies, however, are maintaining a brave face despite the projected headwinds. The UK-EU trade deal announcement arrived in the middle of the pharma industry's Q2 reporting period, where execs were pressed on financial outlooks. In a Q2 earnings call, AbbVie's CEO Rob Michael said the US company is 'fairly insulated' from any tariff-related impacts in 2025, though caveated that the company would not speculate on the longer-term consequences. AstraZeneca shared the same sentiment. CEO Pascal Soriot said the British-Swedish drugmaker is 'almost self-sufficient in terms of supply,' adding that 'tariffs is not an issue that is really affecting us very much.' However, AstraZeneca is on a long list of pharma companies transferring manufacturing to the US. This includes a $4bn investment to build a new manufacturing plant in Virginia. Sanofi has outlaid $20bn to bolster US manufacturing through 2030 and Roche unveiled a similar $50bn investment strategy, to name just a couple. The team at GlobalData added: 'Ultimately, the recent US-EU trade deal has increased the level of uncertainty within the pharmaceutical industry, raising concerns on the potential of tariffs increasing past 15% in the future. 'While the full impact will take time to unfold, it will be interesting to see the adoption of different strategies on how the pharmaceutical industry looks to balance innovation, and ensuring patient access, while managing the pressures of tariffs as they unfold into a certain reality.' A critical part of the industry's future also relies on the outcome of the US government's Section 232 investigation into the drug sector. The probe, which Trump initiated to evaluate the role of medicine imports on national security, could result in further tariffs being imposed. MSD CEO Rob Davis said in the company's Q2 earnings call: 'We need to see more clarity both from the administration and just overall as to how exactly [the 15% tariff] is going to play out. It's still not clear exactly how this relates relative to the February investigation and the timing of whether these apply now or will be phased in until there's further guidance.' AbbVie's Michael said: 'We're having constructive discussions with the administration on sectoral tariffs. Clearly, the best way to motivate that is through tax incentives as well as a trade agenda that prioritises innovation. We're well positioned as a company, but we're not going to be able to really give you any details until we understand the outcome of the 232 investigation.' Navigate the shifting tariff landscape with real-time data and market-leading analysis. Request a free demo for GlobalData's Strategic Intelligence . "Pharma CEOs downplay impact of tariffs amid rising cost concerns" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
4 minutes ago
- Yahoo
Palantir Technologies Inc. (PLTR): A Bear Case Theory
We came across a bearish thesis on Palantir Technologies Inc. on Valueinvesting subreddit by smltc. In this article, we will summarize the bulls' thesis on PLTR. Palantir Technologies Inc.'s share was trading at $158.80 as as of July 25th. PLTR's trailing and forward P/E were 690.43 and 277.78, respectively according to Yahoo Finance. A software engineer manipulating a vast network of code on virtual monitors. Palantir Technologies has emerged as one of the most talked‑about names in the AI boom, with its data analytics platforms Gotham and Foundry, initially designed for intelligence agencies, now widely used by enterprises and governments. The company's newly launched AI platform enables natural‑language querying, further fueling investor excitement about its potential to dominate the AI‑driven data analytics space. Financial performance has been robust, with Q1 2025 revenue rising 39% year‑over‑year to $884 million, U.S. sales up 55%, and commercial revenue surging 71%. Palantir remains profitable, earning $462 million in 2024 and $214 million in the latest quarter, supported by $5.4 billion in cash reserves and no long‑term debt. Its customer base remains heavily skewed toward government contracts, contributing roughly 55% of revenue, and the top 20 clients account for a substantial share, creating concentration risk. Shares have soared more than 400% over the past year, closing around $159 on July 25, propelled by AI optimism. However, the valuation—trading at over 120× trailing sales and 200× next year's earnings—is historically extreme, implying that even modest growth disappointments could lead to steep declines. A discounted cash‑flow analysis, even with bullish assumptions, suggests fair value closer to $20–30 per share, in line with other fast‑growing software peers trading at 8–20× sales. Risks include intensifying competition from tech giants, reliance on large customers, potential government budget tightening, and shareholder dilution from heavy stock‑based compensation. While Palantir's fundamentals remain strong, analysts caution that exuberant pricing leaves little margin for error, making the stock a speculative bet despite its operational momentum. Previously we covered a bullish thesis on Palantir Technologies Inc. (PLTR) by Deep Value Returns in May 2025, which highlighted its strong growth, AI leadership, and profitable scaling despite a premium valuation. The company's stock has appreciated about 46% since, driven by AI optimism. smltc shares a contrarian view and emphasizes extreme valuation risks and downside potential. Palantir Technologies Inc. is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 77 hedge fund portfolios held PLTR at the end of the first quarter which was 64 in the previous quarter. While we acknowledge the potential of PLTR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None.


CNN
6 minutes ago
- CNN
Ukraine is now Trump's war
Donald Trump Russia War in UkraineFacebookTweetLink Follow Vladimir Putin started it. Joe Biden didn't stop it. But, no matter his efforts to the contrary, this is the week in which Russia's invasion of Ukraine becomes US President Donald Trump's war. The most powerful office in the world doesn't always invite choices. Trump is mandated to address the biggest conflict in Europe since World War II because the United States was involved, under his predecessor, as Ukraine's key ally and sponsor. Trump could have dropped the war entirely. But instead, he chose to impose the force of his personality, initially through the idea he could end it in 24 hours, or a revised deadline of 100 days. Then he tried to navigate its personalities, cozying up to the Russian president initially, echoing his narratives and then berating Ukrainian President Volodymyr Zelensky publicly in the Oval Office. He hit his NATO allies hard, demanding they pay more for Europe's defense, which they did. And then the hard slog of diplomacy sputtered into gear, ultimately yielding very little. But it is in the last fortnight that Trump's decisions – and realizations – have turned this into a problem he now owns. He has seen Putin does not want peace. He has seen Ukraine urgently needs arms, and he tried to help, albeit in a lackluster way. He made the remarkable choice of responding to the usually dismissed nuclear saber-rattling of former Russian President Dmitry Medvedev, with harder nuclear threats about positioning US nuclear submarines closer to Russia. The US went from pausing military aid to Ukraine to threatening nuclear force against Russia in less than a month. As this week ends, with Trump's shortened deadline for a peace deal coming into view, he must make perhaps the most consequential decision of the conflict yet. Does he impose penalties – secondary tariffs against Russia's energy customers – that really hurt? Does he accept the US and its allies might need to endure a little pain economically, to inflict pain? Imposing serious secondary sanctions on India and China could roil the global energy market. Trump posted Monday he would be increasing tariffs on India because it was selling Russian crude on at a profit, and he didn't 'care how many people are being killed by the Russian War Machine,' although he did not provide details as to the new measures. India has not made it publicly clear if it intends to stop buying Russian energy products. China is utterly dependent on Russian oil and gas and simply cannot afford to stop buying it. CNN's Nick Paton Walsh describes the riveting escape plan hatched by Ukrainian forces to save the life of an injured soldier pinned down by Russian attacks. To avoid another a 'TACO' moment – short for Trump Always Chickens Out – Trump will have to cause some discomfort and will likely feel some back. Or he can look for an off-ramp, if one is offered to his special envoy Steve Witkoff in an expected Moscow visit this week. Trump could perhaps accept a bilateral meeting with Putin as a sign of progress toward peace. But even this backing down would still mean he has left his indelible imprint on the war – that, in the words of former US Secretary of State Colin Powell regarding Iraq, if the United States breaks it, they own it. Trump cannot have it both ways. It is in his nature to seek to be the fulcrum of all decisions, and the lightning rod of attention, on any given issue. Every turning point so far has been based around his personal choice and fancy. And with this comes a key lesson of the American presidency. Trump does not get to choose which problems are his, and which he can ignore. MAGA's America First platform may be about reducing Washington's global footprint, but it doesn't permit Trump to own solely his successes – and not his failures. Unless Trump reduces the footprint of American power globally to zero – incompatible with a presidential personality compelled to 'do' and agitate – there will always be some problems that are America's. He says he wants wars to stop. But that is not enough in itself. The wars have not all complied. Former US President Barack Obama inherited wars in both Iraq and Afghanistan. He ducked fast out of the former, and doubled down with a surge in the latter, which did not work. Afghanistan became Obama's war, even though it was a mess he had inherited. Trump in turn was passed that mess, and he handed his quick fix to Biden to execute, in the chaotic collapse of August 2021, widely paraded by Republicans as a Democrat failing. Trump faces the same problem of inheriting a crisis. He cannot wish or cajole the conflict to an end. The very battlefield deaths he mourns have sewn damage and grief afar, turning this into an existential war of survival for the Kremlin, and for the soul of Ukrainian society. Ukrainians want to live in peace, without nightly air raid sirens. Putin does not want peace, and instead his most recent maximalist demands amount to something tantamount to Ukrainian surrender. Ultimately, it is reflection of a harsh reality that this should be seen as Trump's war. It is the defining conflict of his presidency and of the post-9/11 era. Its outcome defines European security and Chinese belligerence over the next decade. China understands that and needs Russia to win. Europe understands that, and is arming itself so Russia does not see opportunity in the bloc's weakness. Whether Trump understands this and accepts discomforting, strident decisions with the consequences that follow, we will learn in the week ahead.